Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Dreavent Capital is a Boston-based venture fund founded over 14 years ago, focusing on the biotech sector. The firm actively supports emerging U.S. biopharma companies and has a mission to convert scientific research into innovative patient treatments. Their investment strategy is centered around sectors that promise significant returns.
Dreavent Capital invests in biotech firms specializing in oncology, neurology, cardiovascular & metabolic, and immunology. The firm targets early-stage to growth equity investments, emphasizing immunology due to its potential for developing new therapies. Investment sizes are not specified, but the focus is on sectors ripe for innovation.
Dreavent Capital has backed several notable companies, including Aardvark Therapeutics, which is developing ARD-101 for hyperphagia in Prader-Willi syndrome patients; Chimeron Bio, focused on mRNA cancer vaccine development and recipient of an NIH Innovative Concept Award; and Elicio Therapeutics, which is engaged in clinical studies for T Cell and Antigen Spreading Response.
Submit through their form at dreaventcapital.com.
Yes, Dreavent Capital often leads investment rounds in the biotech sector, particularly in early-stage companies.
The firm is open to follow-on investments, especially in companies that show promising clinical results and growth potential.
Specific fund size details are not disclosed, but the firm has been active in the biotech investment space for over 14 years.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.